scholarly journals Results of surgical treatment of cerebellar astrocytomas in young children

2021 ◽  
Vol 36 (2) ◽  
pp. 25-33
Author(s):  
L.M. Verbova ◽  
A.V. Shaverskyi ◽  
L.L. Marushchenko ◽  
I.P. Protsenko ◽  
V.S. Mykhaliuk ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Surgical Treatment ◽  
Young Children ◽  
Average Duration ◽  
Low Grade ◽  
Diffuse Astrocytoma ◽  
Poorly Differentiated

Objective ‒ to analyze the results of surgical treatment of cerebellar astrocytomas in young children, to establish the factors that determine the prognosis of the course of the disease.Materials and methods. The results of surgical treatment of 112 children with cerebellar astrocytoma, who were operated in Romodanov Neurosurgery Institute of NAMS of Ukraine in 1980‒2019; 59.8 % were boys, 40.2 % were girls. The age of children ‒ from 3 months to 3 years. Removal of the tumor was performed in 106 patients: in 58 ‒ totally, in 31 ‒ subtotally, in 16 ‒ partially, in 1 ‒ biopsy. Diffuse differentiated astrocytoma (low-grade (II)) was detected in 94 (83.9 %) patients, poorly differentiated diffuse astrocytoma (high-grade (III)) ‒ in 18 (16.1 %). In the cerebellum astrocytomas in 77 (68.7 %) cases were located in the midline. In 59 (52.7 %) cases astrocytomas had a cystic component, in 53 (47.3 %) cases were solid ones. Postoperative mortality over 30 years of observations was 15.2 %. Results. It was found that survival rates in the early postoperative period were statistically (p = 0.03) better in cases of total tumor resection compared with patients after with subtotal resection. In patients with diffuse differentiated astrocytoma of the cerebellum, the average duration of follow-up was 6.7 years, a good quality of life was noted in 39.4 % of patients. In the long-term follow-up period, 7.3 % of children died. In patients with poorly differentiated diffuse astrocytoma of the cerebellum, the average duration of follow-up was 4.3 years, while a satisfactory quality of life was observed in 68.0 % of patients, a poor quality in 22.0 %, and a vegetative state in 10.0 % of children. In the long-term period, 20.0 % of children died. Microscopic features of cerebellar astrocytomas are their expansive-infiltrative nature of distribution and the presence of zones of neoangiomatosis.Conclusions. It was revealed that the degree of differentiation of diffuse cerebellar astrocytomas and the radicality of their removal correlates with the quality and life expectancy of patients. The tendency of the influence of the degree of malignancy of astrocytomas on the indicators of general and reccurence-free survival of children of the younger age group was noted.

Quality of life after surgical treatment of coarctation in long-term follow-up (CoAFU): Predictive value of clinical variables

2018 ◽  
Vol 250 ◽  
pp. 116-119 ◽  
Author(s):  
Pinar Bambul Heck ◽  
Jelena Pabst von Ohain ◽  
Harald Kaemmerer ◽  
Peter Ewert ◽  
Alfred Hager
Keyword(s):  
Quality Of Life ◽  
Surgical Treatment ◽  
Predictive Value ◽  
Clinical Variables ◽  
Long Term Follow Up

OS09.4.A Health-related quality of life in low-grade glioma survivors 26 years after diagnosis

2021 ◽  
Vol 23 (Supplement_2) ◽  
pp. ii12-ii12
Author(s):  
F W Boele ◽  
J C Reijneveld ◽  
P C de Witt Hamer ◽  
H F van Thuijl ◽  
P Wesseling ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Low Grade ◽  
Group Level ◽  
Related Quality ◽  
Health Related ◽  
Changes Over Time ◽  
Over Time

Abstract BACKGROUND Many patients with low-grade gliomas (LGGs) continue to survive for many years, yet little is known about patients’ health-related quality of life (HRQOL) in long-term survivorship. We previously investigated HRQOL in LGG patients diagnosed on average 6 years prior to assessment (T1, N=195) with a follow-up in stable patients on average 12 years after diagnosis (T2, N=65). We present a final follow-up of LGG survivors (T3), now decades after diagnosis. MATERIAL AND METHODS We invited patients who participated in our previous assessment (N=65), regardless of disease status. Patients completed questionnaires to assess HRQOL, fatigue, and depressive symptoms: Short Form-36 Health Survey (SF-36), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Brain Tumour Module (EORTC BN20), Checklist Individual Strength (CIS), and the Center for Epidemiological Studies Depression Scale (CES-D). Changes over time (T1-T2-T3) on group level and participant level were assessed. RESULTS Of the 65 patients, 18 (27.7%) were deceased, 3 (4.6%) experienced tumour progression to WHO III, 7 (10.8%) declined, and 3 (4.6%) could not be contacted. Thirty-four patients (52.3%) participated. Of these, 2 had missing HRQOL data, with 32 patients included in analysis. Survivors were M=52.0 (sd=11.3) years old and diagnosed M=26.2 (sd=3.7, range 19–35) years prior. On group level, a statistically significant (but not clinically relevant) improvement in mental health (p=0.049), and a clinically relevant (but not statistically significant) decline in emotional role functioning was found. No other group-level changes over time in HRQOL were found. Minimal detectable change in HRQOL scale scores over time was observed in individual participants (28.1% only improvement; 25.0% only decline; 21.9% both improvement and decline) with 25.0% remaining completely stable. At T3, 25.0% of survivors scored above the cut-off for high risk of clinical depression (≥16 CES-D), and 53.1% of survivors classed as severely fatigued (≥35 CIS). CONCLUSION In this cohort of LGG survivors, assessed decades after diagnosis and treatment, HRQOL does not appear to be greatly impacted during survivorship. However, depressive symptoms and fatigue remain relatively common. Findings can help inform patients, their families, and clinicians and can serve as a benchmark for treatment trials evaluating interventions that can have very long-term effects.

Gamma Knife Radiosurgery for Low-Grade Gliomas: Clinical Results at Long-Term Follow-Up of Tumor Control and Patients' Quality of Life

2017 ◽  
Vol 101 ◽  
pp. 540-553 ◽  
Author(s):  
Filippo Gagliardi ◽  
Michele Bailo ◽  
Alfio Spina ◽  
Carmine A. Donofrio ◽  
Nicola Boari ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gamma Knife ◽  
Gamma Knife Radiosurgery ◽  
Clinical Results ◽  
Tumor Control ◽  
Low Grade ◽  
Long Term Follow Up

Health-Related Quality of Life in Stable, Long-Term Survivors of Low-Grade Glioma

2015 ◽  
Vol 33 (9) ◽  
pp. 1023-1029 ◽  
Author(s):  
Florien W. Boele ◽  
Linda Douw ◽  
Jaap C. Reijneveld ◽  
Rianne Robben ◽  
Martin J.B. Taphoorn ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Stable Disease ◽  
Low Grade ◽  
Sf 36 ◽  
Related Quality ◽  
Long Term Follow Up ◽  
Health Related

Purpose Patients with low-grade glioma (LGG) often experience long periods of stable disease, emphasizing the importance of maintaining good health-related quality of life (HRQOL). We assessed the changes in HRQOL in long-term survivors of WHO grade I or II astrocytoma, oligodendroglioma, or oligoastrocytoma with clinically and radiologically stable disease. Patients and Methods Patients completed self-report measures of generic HRQOL (Short Form-36 [SF-36]) and disease-specific HRQOL (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Brain Cancer Module). Assessments took place at midterm and long-term follow-up, on average 6 and 12 years after histologic diagnosis and initial treatment, respectively. Comparisons between patients with LGG and individually matched healthy controls were made, and change within the patients with LGG was calculated, as was minimal detectable change. Results Although no statistically significant differences between patients with LGG and healthy matched controls were found at midterm follow-up, patients with LGG had worse physical role functioning (P = .004) and general health perceptions (P = .004) than controls at long-term follow-up. Within patients with stable LGG (n = 65), physical HRQOL (the SF-36 physical component summary and the physical functioning subscale) was significantly worse at long-term than at midterm follow-up (both P < .001). Although 48% of patients improved or remained stable on all HRQOL scales, 38.5% of patients experienced detectable decline on one or more scales. Conclusion Although HRQOL remains mostly preserved in the majority of patients with LGG, a subset of patients experience detectable decline on one or more HRQOL scales despite long-term stable disease. For this subgroup, further research is recommended to better aid patients in dealing with the consequences of LGG.

Long-term outcome and quality of life of dogs that developed neurologic signs after surgical treatment of a congenital portosystemic shunt: 50 cases (2005–2020)

2021 ◽  
pp. 1-9
Author(s):  
Antía Escribano Carrera ◽  
Anya M. Morrissey ◽  
Victoria J. Lipscomb ◽  
Michael S. Tivers ◽  
Alex Chan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Surgical Treatment ◽  
Portosystemic Shunt ◽  
Survival Times ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Congenital Portosystemic Shunt

Abstract OBJECTIVE To determine survival time and quality of life of dogs that developed postattenuation neurologic signs (PANS) after surgical treatment of a single congenital portosystemic shunt and survived at least 30 days and identify whether neurologic signs present at the time of discharge would resolve or reoccur. ANIMALS 50 client-owned dogs. PROCEDURES Medical records were retrospectively reviewed, and follow-up data relating to neurologic signs and seizure activity were obtained. Owners were asked to complete a questionnaire related to the presence of neurologic signs, including seizures, and their dog’s quality of life. RESULTS Thirty of the 50 (60%) dogs had postattenuation seizures with or without other nonseizure neurologic signs, and 20 (40%) had neurologic signs other than seizures. Neurologic signs had fully resolved by the time of discharge in 24 (48%) dogs. Signs resolved in 18 of the remaining 26 (69%) dogs that still had PANS other than seizures at the time of discharge. Seizures reoccurred in 15 of the 30 dogs that had postattenuation seizures. Twenty-seven of 33 (82%) owners graded their dog’s long-term (> 30 days after surgery) quality-of-life as high. Forty-five (90%) dogs survived > 6 months. Most (29/43 [67%]) neurologic signs (other than seizures) present at the time of hospital discharge resolved. CLINICAL RELEVANCE Findings highlighted that survival times of > 6 months and a high QOL can be achieved in most dogs with PANS that survive at least 30 days. Most neurologic signs other than seizures resolved within 1 month postoperatively. Half of the dogs with postattenuation seizures had a reoccurrence.

QOLP-05. HEALTH-RELATED QUALITY OF LIFE IN LOW-GRADE GLIOMA SURVIVORS 26 YEARS AFTER DIAGNOSIS

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi183-vi183
Author(s):  
Florien Boele ◽  
Jaap Reijneveld ◽  
Philip de Witt Hamer ◽  
Hinke van Thuijl ◽  
Pieter Wesseling ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Low Grade ◽  
Group Level ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Over Time

Abstract BACKGROUND Patients with low-grade gliomas (LGGs) often survive for many years, yet little is known about patients’ health-related quality of life (HRQOL) in long-term survivorship. We previously investigated HRQOL in LGG patients diagnosed on average 6 years prior to assessment (T1, N=195) with a follow-up in stable patients on average 12 years after diagnosis (T2, N=65). We present a final follow-up of LGG survivors (T3), now decades after diagnosis. METHODS Patients completed questionnaires to assess HRQOL (Short Form-36 Health Survey; EORTC-BN20), fatigue (Checklist Individual Strength (CIS)), and depressive symptoms (Center for Epidemiological Studies-Depression Scale (CES-D)). Changes over time (T1-T2-T3) on group level and participant level were assessed. RESULTS Of the 65 patients approached, 18 (27.7%) were deceased, 3 (4.6%) experienced tumour progression to WHO III, 7 (10.8%) declined, and 3 (4.6%) could not be contacted. Thirty-four patients (52.3%) participated (missing HRQOL data N=2; N=32 included in analysis). Survivors were M=52.0 (sd=11.3) years old and diagnosed M=26.2 (sd=3.7, range:19-35) years prior. On group level, a statistically significant (but not clinically relevant) improvement in mental health (p=0.049), and a clinically relevant (but not statistically significant) decline in emotional role functioning was found. Minimal detectable change in HRQOL scale scores over time was observed in individual participants (28.1% only improvement; 25.0% only decline; 21.9% both improvement and decline) with 25.0% remaining completely stable. At T3, 25.0% and 53.1% of survivors scored above the cut-off for high risk of depression (≥16 CES-D) and severe fatigue (≥35 CIS), respectively. CONCLUSION In LGG survivors, assessed decades after diagnosis and treatment, HRQOL does not appear to be greatly impacted during survivorship. However, depressive symptoms and fatigue remain relatively common. Findings can help inform patients, their families, and clinicians and can serve as a benchmark for treatment trials evaluating interventions that can have very long-term effects.

Sign in / Sign up

Export Citation Format

Share Document